AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
ASTRAZENECA PHARMA | SANOFI INDIA | ASTRAZENECA PHARMA/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 134.3 | 42.9 | 313.1% | View Chart |
P/BV | x | 37.7 | 8.7 | 431.8% | View Chart |
Dividend Yield | % | 0.0 | 1.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
SANOFI INDIA Dec-18 |
ASTRAZENECA PHARMA/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 6,840 | 18.7% | |
Low | Rs | 883 | 4,630 | 19.1% | |
Sales per share (Unadj.) | Rs | 228.4 | 1,203.1 | 19.0% | |
Earnings per share (Unadj.) | Rs | 10.4 | 165.3 | 6.3% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 209.9 | 7.7% | |
Dividends per share (Unadj.) | Rs | 0 | 84.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 963.6 | 10.3% | |
Shares outstanding (eoy) | m | 25.00 | 23.03 | 108.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 4.8 | 99.2% | |
Avg P/E ratio | x | 104.2 | 34.7 | 300.4% | |
P/CF ratio (eoy) | x | 66.4 | 27.3 | 243.1% | |
Price / Book Value ratio | x | 10.9 | 6.0 | 183.8% | |
Dividend payout | % | 0 | 50.8 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 132,078 | 20.4% | |
No. of employees | `000 | 1.4 | 3.3 | 41.1% | |
Total wages/salary | Rs m | 1,535 | 4,068 | 37.7% | |
Avg. sales/employee | Rs Th | 4,210.9 | 8,393.8 | 50.2% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,232.4 | 91.9% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,153.0 | 16.6% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 27,708 | 20.6% | |
Other income | Rs m | 123 | 897 | 13.7% | |
Total revenues | Rs m | 5,833 | 28,605 | 20.4% | |
Gross profit | Rs m | 463 | 6,235 | 7.4% | |
Depreciation | Rs m | 147 | 1,027 | 14.4% | |
Interest | Rs m | 0 | 7 | 0.0% | |
Profit before tax | Rs m | 438 | 6,098 | 7.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 2,292 | 7.8% | |
Profit after tax | Rs m | 259 | 3,806 | 6.8% | |
Gross profit margin | % | 8.1 | 22.5 | 36.0% | |
Effective tax rate | % | 40.8 | 37.6 | 108.7% | |
Net profit margin | % | 4.5 | 13.7 | 33.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 15,922 | 20.2% | |
Current liabilities | Rs m | 2,070 | 6,235 | 33.2% | |
Net working cap to sales | % | 20.0 | 35.0 | 57.1% | |
Current ratio | x | 1.6 | 2.6 | 60.7% | |
Inventory Days | Days | 72 | 64 | 113.7% | |
Debtors Days | Days | 35 | 21 | 167.4% | |
Net fixed assets | Rs m | 790 | 7,539 | 10.5% | |
Share capital | Rs m | 50 | 230 | 21.7% | |
"Free" reserves | Rs m | 2,419 | 21,962 | 11.0% | |
Net worth | Rs m | 2,469 | 22,192 | 11.1% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 4,605 | 29,839 | 15.4% | |
Interest coverage | x | NM | 872.1 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.2 | 0.9 | 133.5% | |
Return on assets | % | 5.6 | 12.8 | 44.0% | |
Return on equity | % | 10.5 | 17.2 | 61.2% | |
Return on capital | % | 17.7 | 27.5 | 64.5% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 7,587 | 3.9% | |
Fx outflow | Rs m | 2,015 | 7,145 | 28.2% | |
Net fx | Rs m | -1,715 | 442 | -388.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 3,739 | 2.4% | |
From Investments | Rs m | -94 | -731 | 12.8% | |
From Financial Activity | Rs m | NA | -1,972 | 0.0% | |
Net Cashflow | Rs m | -6 | 1,036 | -0.6% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 60.4 | 124.2% | |
Indian inst/Mut Fund | % | 0.3 | 14.4 | 2.1% | |
FIIs | % | 15.7 | 14.6 | 107.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 10.5 | 86.7% | |
Shareholders | 12,856 | 15,184 | 84.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: ABBOTT INDIA NATCO PHARMA DIVIS LABORATORIES IPCA LABS ALKEM LABORATORIES
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More